|
Melanoma prevention by MC1R selective small peptide analogs of alpha MSH
|
1R21CA191761-01A1
|
$221,595
|
$221,595
|
ABDEL-MALEK, ZALFA
|
UNIVERSITY OF CINCINNATI
|
|
How p16 and MC1R mutations synergistically exacerbate melanoma risk.
|
5R21CA183440-02
|
$170,285
|
$170,285
|
ABDEL-MALEK, ZALFA
|
UNIVERSITY OF CINCINNATI
|
|
Hereditary cancer predisposition syndromes and uveal melanoma
|
1R21CA191943-01
|
$200,970
|
$200,970
|
ABDEL-RAHMAN, MOHAMED
|
OHIO STATE UNIVERSITY
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
5U10CA180791-02
|
$737,200
|
$36,860
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Role of SIRT1 in melanocyte biology and melanocyte transformation
|
5R01CA176748-03
|
$314,176
|
$314,176
|
AHMAD, NIHAL
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
Prospective study of farmers and their families (Agricultural health study)
|
ZIA CP010119 - 02020
|
$430,051
|
$21,503
|
Alavanja, Michael
|
DCEG (NCI)
|
|
Medical University of South Carolina - Cancer Center Support Grant
|
3P30CA138313-07S1
|
$34,031
|
$2,722
|
ALBERG, ANTHONY
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
Medical University of South Carolina - Cancer Center Support Grant
|
3P30CA138313-07S2
|
$250,000
|
$20,000
|
ALBERG, ANTHONY
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
Medical University of South Carolina - Cancer Center Support Grant
|
3P30CA138313-07S3
|
$124,997
|
$10,000
|
ALBERG, ANTHONY
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
Medical University of South Carolina - Cancer Center Support Grant
|
5P30CA138313-07
|
$1,495,000
|
$119,600
|
ALBERG, ANTHONY
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Sit
|
5U10CA180790-02
|
$1,295,864
|
$51,835
|
ALBERTS, STEVEN
|
MAYO CLINIC ROCHESTER
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-46S1
|
$138,748
|
$63,824
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-46
|
$2,578,347
|
$1,186,040
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
OAS1 activation by endogenous dsRNAs during growth arrest and cancer pathogenesis
|
5F32CA183423-02
|
$56,042
|
$56,042
|
ALTSCHULER, SARAH
|
UNIVERSITY OF UTAH
|
|
NCTN Deep South Research Consortium
|
3U10CA180855-02S1
|
$199,999
|
$20,000
|
ALVAREZ, RONALD
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
NCTN Deep South Research Consortium
|
5U10CA180855-02
|
$497,800
|
$49,780
|
ALVAREZ, RONALD
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Molecular mechanisms of BRAF inhibitor induced UPR and autophagy
|
1R01CA198015-01
|
$366,000
|
$366,000
|
AMARAVADI, RAVI
|
UNIVERSITY OF PENNSYLVANIA
|
|
HLTF gene silencing: a novel determinant of sensitivity to autophagy inhibition
|
5R01CA169134-03
|
$312,942
|
$156,471
|
AMARAVADI, RAVI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Sensitization to CD47 Blockade to Enhance Anti-Tumor Immunity
|
1F30CA195973-01
|
$41,990
|
$41,990
|
ANDERSON, KATIE
|
UNIVERSITY OF MINNESOTA
|
|
Obesity and mortality after breast cancer diagnosis by race/ethnicity in the WHI
|
3UM1CA173642-03S1
|
$113,842
|
$18,215
|
ANDERSON, GARNET
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Women's Health Initiative Cancer Survivor Cohort
|
5UM1CA173642-03
|
$2,539,856
|
$406,377
|
ANDERSON, GARNET
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Mutant BRAF-regulated transcription factors in melanoma progression
|
1R01CA196278-01
|
$356,660
|
$356,660
|
APLIN, ANDREW
|
THOMAS JEFFERSON UNIVERSITY
|
|
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to RAF inhibitors
|
3R01CA160495-04S1
|
$14,229
|
$14,229
|
APLIN, ANDREW
|
THOMAS JEFFERSON UNIVERSITY
|
|
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to RAF inhibitors
|
5R01CA160495-04
|
$321,625
|
$321,625
|
APLIN, ANDREW
|
THOMAS JEFFERSON UNIVERSITY
|
|
Targeted therapies in mutant BRAF melanoma
|
5R01CA182635-02
|
$321,625
|
$321,625
|
APLIN, ANDREW
|
THOMAS JEFFERSON UNIVERSITY
|
|
Hutchinson Center as Lead Academic Participating Site (U10)
|
5U10CA180828-02
|
$557,728
|
$27,886
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Cancer Center Support Grant
|
3P30CA082103-17S2
|
$50,000
|
$500
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-17S3
|
$124,967
|
$1,250
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-17S4
|
$199,969
|
$2,000
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-17S5
|
$158,600
|
$1,586
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
5P30CA082103-17
|
$7,292,969
|
$72,930
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Impact of Melanoma Genetic Testing on Health Cognitions and Prevention Behaviors
|
5R01CA158322-05
|
$355,697
|
$355,697
|
ASPINWALL, LISA
|
UNIVERSITY OF UTAH
|
|
IL-27-based cancer vaccination approach for cancer immunotherapy
|
1R21CA198037-01
|
$167,475
|
$83,738
|
BAI, XUE-FENG
|
OHIO STATE UNIVERSITY
|
|
Elucidating the role of CD26 in T cell-mediated tumor immunity
|
1F31CA192787-01
|
$43,120
|
$43,120
|
BAILEY, STEFANIE
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-41S1
|
$37,429
|
$2,620
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-41S2
|
$125,000
|
$8,750
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive Cancer Center Support
|
5P30CA014520-41
|
$4,288,496
|
$300,195
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
Vesicular Stomatitis Virus (VSV) Replication in Malignant Cells
|
1R01CA194404-01
|
$332,363
|
$99,709
|
BARBER, GLEN
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
Molecular Basis for Small Molecule STAT3 Inhibition
|
5F32CA180298-04
|
$56,042
|
$56,042
|
BARBER-ROTENBERG, JULIE
|
UNIVERSITY OF PENNSYLVANIA
|
|
The GNAQ pathway as a therapeutic target in uveal melanoma
|
5R01CA142873-06
|
$310,970
|
$310,970
|
BASTIAN, BORIS
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Translational Studies of the Histone Deacetylase Inhibitor Romidepsin
|
ZIA BC 010621
|
$853,079
|
$170,616
|
Bates, Susan
|
CCR (NCI)
|
|
Cancer Center Support Grant
|
2P30CA042014-26
|
$1,639,000
|
$196,680
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-26S1
|
$31,248
|
$3,750
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-26S2
|
$50,000
|
$6,000
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-26S3
|
$249,799
|
$29,976
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-26S4
|
$123,315
|
$14,798
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-26S5
|
$150,000
|
$18,000
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-26S6
|
$178,513
|
$21,422
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Targeting an MT1-MMP/MMP2 axis in melanoma by a novel MT1-MMP/MMP2 inhibitor
|
1R21CA187695-01A1
|
$217,926
|
$217,926
|
BEDOGNI, BARBARA
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Targeting the developmental pathways Notch and ERBB for melanoma therapy
|
5R01CA177652-02
|
$358,346
|
$358,346
|
BEDOGNI, BARBARA
|
CASE WESTERN RESERVE UNIVERSITY
|
Total relevant funding to Melanoma for this search: $132,793,176
|